| 1. Increasing cord blood cell dose |
| · Improved CB collection, processing, freezing, and thawing. |
| · Consecutive infusion of two CBUs (RS; Prospective phase II/III clinical trials; Clinical use). |
| · Ex vivoexpansion of CB (Phase I/II/III clinical trials). |
| · Infusion of CBU with third-party donor cells (Phase II clinical trials). |
| 2. Improved delivery and homing HSC to bone marrow niche |
| · Direct intra-bone infusion of CB (Phase I/II clinical trials). |
| · Inhibition of CD26 peptidase (Phase II clinical trials). |
| · Ex vivo Fucosylation of CB HSC/HPC (Phase I/II clinical trials). |
| 3. Improved selection of CBU |
| ·Enhanced HLA-matching (RS; PSO). |
| ·Detection of donor specific HLA-antibodies (RS; PSO). |
| ·Use of KIR matching (RS). |
| 4. Modification of transplant protocol |
| · Using reduced intensity conditioning (RS; Prospective phase II/III clinical trials; Clinical use). |
| · Modification of graft-versus-host disease prophylaxis (RS; PSO). |
| 5. Post-transplant use of growth factors/cytokines |
| · Administration of granulocyte colony stimulating factor (GCSF) (Regular clinical use). |
| · Administration of stem cell factor (SCF) (Pre-clinical studies). |
| · Administration of Eltrombopag (Phase II clinical trials). |
| 6. Infusion of CB with accessory cells |
| · Use of Mesenchymal stem cells (Phase I/II clinical trials). |
| · Use of regulatory T cells (Phase I/II clinical trials). |
